Metastatic Disease: Clinical Trials

6 trials for Metastatic Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 2 completed, 1 recruiting. 6 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Terminated 3, Completed 2, Recruiting 1
Phase 22Recruiting 1, Terminated 1

Follow Metastatic Disease: new trials by email Literature Review of Metastatic Disease trials Research Report on Metastatic Disease

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy) - Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced
Phase 1 / Phase 2RecruitingBeijing Biotech422026-03-022026-06-04
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
Promitil, EBR - Cancer, Solid Tumor
Phase 1CompletedLipomedix Pharmaceuticals Inc.182019-01-032022-01-06
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
AR-42, Pazopanib - Renal Cell Carcinoma, Soft Tissue Sarcoma
Phase 1TerminatedVirginia Commonwealth University62016-07-082019-10-24
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
BIBW 2992 - Metastatic Disease
Phase 1TerminatedJohannes Gutenberg University Mainz92012-08-012019-09-06
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Temsirolimus, Casodex (bicalutamide) - Prostate Cancer, Prostatic Neoplasms
Phase 1 / Phase 2TerminatedSandy Srinivas52009-10-012014-10-13
Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone
intensity modulated radiation therapy - Metastatic Disease
Phase 1CompletedMemorial Sloan Kettering Cancer Center682006-08-012015-11-17

Narrower conditions

Neoplasm Metastasis (6)  ·  Biliary Tract Neoplasms (1)  ·  Carcinoma, Renal Cell (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Sarcoma (1)

Broader conditions

Neoplastic Processes (6)  ·  Pathologic Processes (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Neoplasms (5)  ·  Neoplasms by Site (4)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Male Urogenital Diseases (2)  ·  Urogenital Diseases (2)  ·  Urogenital Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Biliary Tract Diseases (1)  ·  Carcinoma (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)

Interventions

Afatinib (1)  ·  Cisplatin (1)  ·  Cyclophosphamide (1)  ·  Gemcitabine (1)  ·  HDAC-42 (1)  ·  Radiotherapy, Intensity-Modulated (1)  ·  Transplantation Conditioning (1)  ·  bicalutamide (1)  ·  fludarabine (1)  ·  pazopanib (1)  ·  temsirolimus (1)

Sponsors

Beijing Biotech (1)  ·  Johannes Gutenberg University Mainz (1)  ·  Lipomedix Pharmaceuticals Inc. (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Sandy Srinivas (1)  ·  Virginia Commonwealth University (1)

Countries

United States (3)  ·  China (1)  ·  Germany (1)  ·  Israel (1)

Top investigators

Adi Levy, MD (1)  ·  Andrew S Poklepovic, MD (1)  ·  Eli Sapir, MD (1)  ·  Lauren Christine Harshman, MD (1)  ·  Markus Moehler, Prof. Dr. med. (1)  ·  Michael Zelefsky, MD (1)

Results publications

PMID 30634942

NIH funding

P30CA016059 (1)